E
Entera Bio
Innovative oral protein and peptide therapies for chronic disease management, eliminating the need for injections
About Entera Bio
Entera Bio is a clinical-stage global company addressing high unmet clinical needs by developing first-in-class, daily oral protein and peptide replacement therapies. These therapies are designed to improve the standard of care for patients managing chronic diseases, allowing them to live healthier lives without the need for injections. Entera Bio's lead program focuses on creating the first oral osteoanabolic bone-forming daily tablet to treat osteoporosis, a condition that predominantly affects women and currently relies on injectable treatments. The company operates in the biopharmaceutical market, targeting patients with chronic conditions who require ongoing treatment. Entera Bio's business model involves the research, development, and commercialization of these innovative oral therapies. Revenue is generated through product sales, partnerships, and potential licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Jerusalem, Israel
- Listing
- IPO 2018
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 76.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Jul 2026 | $275M | — | BVF Partners | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2026 | $10M | — | BVF Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $42K | 0% | −$11M | -27378.6% |
| 2025 | $42K | -76.8% | −$11M | -27378.6% |
| 2024 | $181K | — | −$9.5M | -5270.2% |
| 2023 | $0 | -100% | −$8.8M | — |
| 2022 | $134K | -76.5% | −$13M | -9714.2% |
| 2021 | $571K | +56.4% | −$12M | -2130.3% |
| 2020 | $365K | — | −$11M | -3050.1% |
Growth signals
Latest recorded traffic for Entera Bio is 5.6K monthly website visits, up 93.1% over the last three months. Entera Bio's team grew 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Pontifax Funds
Other known investors1 additional known investor
BVF Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Entera Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Entera Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.